3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Asthma
2
Smoking
1
Pulmonary Disease, Chronic Obstructive
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Leukemia, Plasma Cell
1
Leukemia
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Interventions
Dexamethasone
10
fludarabine phosphate
9
Melphalan
9
fludarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Lenalidomide
7
Cyclophosphamide
7
Mycophenolic Acid
6
Bortezomib
6
Tacrolimus
5
Calcium Dobesilate
4
filanesib
3
dexamethasone acetate
3
dexamethasone 21-phosphate
3
daratumumab
3
carfilzomib
3
auricularum
3
Stem Cell Transplantation
3
Sirolimus
3
Filgrastim
3
liposomal doxorubicin
2
ixazomib
2
Steroids
2
Injections, Subcutaneous
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Cytarabine
2
Cyclosporine
2
Carmustine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Leukemia, Plasma Cell
×
Budesonide
×
Clear all
NCT05405387
2026-06-05
IMPACT
University of Utah
Phase 2
Recruiting
120 enrolled